Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Inhibrx Biosciences, Inc. (INBX) since 2024 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Inhibrx Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 2007919.
Total stock buying since 2024: $9,688,918.
Total stock sales since 2024: $0.
Total stock option exercises since 2024: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 603,778 | $9,688,918 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-10 | 6,667 | $100,005 | 0 | $0 | 0 | $0 |
| 2024-09 | 110,636 | $1,719,957 | 0 | $0 | 0 | $0 |
| 2024-08 | 142,140 | $1,936,068 | 0 | $0 | 0 | $0 |
| 2024-06 | 274,142 | $4,799,973 | 0 | $0 | 0 | $0 |
| 2024-05 | 70,193 | $1,132,915 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-10-03 | Vuori Kristiina Md (Director) | Buy | 6,667 | 15.00 | 100,005 |
| 2024-09-16 | Lappe Mark (Chief Executive Officer) | Buy | 13,037 | 17.13 | 223,323 |
| 2024-09-12 | Lappe Mark (Chief Executive Officer) | Buy | 26,963 | 15.05 | 405,793 |
| 2024-09-11 | Vuori Kristiina Md (Director) | Buy | 6,457 | 15.07 | 97,306 |
| 2024-09-10 | Vuori Kristiina Md (Director) | Buy | 179 | 15.00 | 2,685 |
| 2024-09-10 | Lappe Mark (Chief Executive Officer) | Buy | 8,500 | 15.19 | 129,115 |
| 2024-09-09 | Lappe Mark (Chief Executive Officer) | Buy | 9,500 | 15.21 | 144,495 |
| 2024-09-06 | Lappe Mark (Chief Executive Officer) | Buy | 26,000 | 15.29 | 397,540 |
| 2024-09-03 | Lappe Mark (Chief Executive Officer) | Buy | 20,000 | 15.98 | 319,700 |
| 2024-08-30 | Lappe Mark (Chief Executive Officer) | Buy | 10,000 | 14.02 | 140,200 |
| 2024-08-29 | Vuori Kristiina Md (Director) | Buy | 7,140 | 14.00 | 99,960 |
| 2024-08-29 | Lappe Mark (Chief Executive Officer) | Buy | 10,000 | 14.03 | 140,300 |
| 2024-08-23 | Forsyth Douglas (Director) | Buy | 59,812 | 14.07 | 841,554 |
| 2024-08-22 | Forsyth Douglas (Director) | Buy | 15,188 | 12.89 | 195,773 |
| 2024-08-21 | Lappe Mark (Chief Executive Officer) | Buy | 12,945 | 12.93 | 167,378 |
| 2024-08-20 | Lappe Mark (Chief Executive Officer) | Buy | 27,055 | 12.97 | 350,903 |
| 2024-06-05 | Kayyem Jon Faiz (Director) | Buy | 57,549 | 17.56 | 1,010,560 |
| 2024-06-04 | Kayyem Jon Faiz (Director) | Buy | 89,063 | 17.84 | 1,588,883 |
| 2024-06-03 | Kayyem Jon Faiz (Director) | Buy | 127,530 | 17.25 | 2,200,530 |
| 2024-05-31 | Kayyem Jon Faiz (Director) | Buy | 70,193 | 16.14 | 1,132,915 |
Insider trading activities including stock purchases, stock sales, and option exercises of INBX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Inhibrx Biosciences, Inc. (symbol INBX, CIK number 2007919) see the Securities and Exchange Commission (SEC) website.